Short Interest in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Expands By 8.1%

Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 9,500,000 shares, an increase of 8.1% from the December 15th total of 8,790,000 shares. Based on an average trading volume of 1,670,000 shares, the short-interest ratio is presently 5.7 days. Approximately 7.6% of the shares of the stock are sold short.

Halozyme Therapeutics Stock Down 1.0 %

Shares of HALO opened at $54.80 on Monday. The firm has a market capitalization of $6.97 billion, a P/E ratio of 18.15, a P/E/G ratio of 0.40 and a beta of 1.24. Halozyme Therapeutics has a 12-month low of $33.15 and a 12-month high of $65.53. The firm has a fifty day moving average price of $49.62 and a 200-day moving average price of $54.12. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the sale, the director now owns 43,611 shares of the company’s stock, valued at $2,180,986.11. The trade was a 18.65 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 2.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Janney Montgomery Scott LLC raised its stake in shares of Halozyme Therapeutics by 698.8% during the fourth quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company’s stock valued at $13,756,000 after acquiring an additional 251,711 shares in the last quarter. Sugar Maple Asset Management LLC bought a new stake in Halozyme Therapeutics during the 4th quarter valued at $373,000. Diversify Advisory Services LLC lifted its holdings in shares of Halozyme Therapeutics by 9.3% in the 4th quarter. Diversify Advisory Services LLC now owns 5,825 shares of the biopharmaceutical company’s stock worth $308,000 after buying an additional 494 shares during the period. Diversify Wealth Management LLC lifted its holdings in shares of Halozyme Therapeutics by 63.8% in the 4th quarter. Diversify Wealth Management LLC now owns 15,464 shares of the biopharmaceutical company’s stock worth $816,000 after buying an additional 6,025 shares during the period. Finally, Empirical Asset Management LLC bought a new position in shares of Halozyme Therapeutics during the 4th quarter worth $1,091,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. JMP Securities increased their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. HC Wainwright upped their price objective on Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Piper Sandler lifted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Finally, Wells Fargo & Company decreased their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $60.89.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.